Hims adheres strictly to all the regulations set forth by all applicable Colleges of Pharmacists and Colleges of Physicians and Surgeons in which we operate
Cardiovascular outcome trials have established benefits for specific agents: the LEADER trial for liraglutide, SUSTAIN-6 for injectable semaglutide, and REWIND for dulaglutide demonstrated reduced risk of major adverse cardiovascular events in patients with type 2 diabetes
Compounded GLP-1 Receptor Agonists Remain Widely Available WEDNESDAY, July 22, 2026 -- Despite the end of nationwide shortages of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the market for compounded GLP-1 RA alternatives
Semaglutide and tirzepatide achieve approximately 15-20% body weight reduction in clinical trials
Fast shipping easy to use
GLP-1 induces FNDC5 expression in -cells via CREB, promoting WAT to BAT conversion